Epirubicin
- Generic Name
- Epirubicin
- Brand Names
- Ellence, Pharmorubicin PFS
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 56420-45-2
- Unique Ingredient Identifier
- 3Z8479ZZ5X
- Background
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
- Indication
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
- Associated Conditions
- Breast Cancer, Breast Cancer, Stage II, Breast Cancer, Stage III, Colorectal Cancer, Hormone-Refractory Prostate Cancer, Neoplasm of Stomach, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Papillary transitional cell carcinoma of bladder, Recurrent Superficial Bladder Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Carcinoma in situ of urinary bladder
- Associated Therapies
- -
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1728
- Registration Number
- NCT06112379
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2023-08-09
- Target Recruit Count
- 181
- Registration Number
- NCT05983094
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2023-08-08
- Target Recruit Count
- 196
- Registration Number
- NCT05981014
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- wang shusen
- Target Recruit Count
- 116
- Registration Number
- NCT05978648
- Locations
- 🇨🇳
Sun-yat sen university cancer center, Guangzhou, Gangdong, China
TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1736
- Registration Number
- NCT05901428
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Karolinska University Hospital
- Target Recruit Count
- 370
- Registration Number
- NCT05900206
- Locations
- 🇸🇪
Stockholm Southern Hospital, Stockholm, Sweden
🇸🇪Skåne University Hospital, Malmö, Sweden
🇸🇪Sankt Gorans Hospital, Stockholm, Sweden
Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors
- Conditions
- Interventions
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Liaoning Tumor Hospital & Institute
- Target Recruit Count
- 30
- Registration Number
- NCT05887726
- Locations
- 🇨🇳
Xing Xiaojing, Shenyang, Liaoning, China
EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1406
- Registration Number
- NCT05883852
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China
A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2023-01-12
- Target Recruit Count
- 26
- Registration Number
- NCT05681728
- Locations
- 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2023-01-10
- Target Recruit Count
- 200
- Registration Number
- NCT05678933
- Locations
- 🇨🇳
Tianjin Medical University Cancer Insititute & Hospital, Tianjin, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.